The alpha mannosidosis market size has grown rapidly in recent years. It will grow from $15.1 billion in 2024 to $18.02 billion in 2025 at a compound annual growth rate (CAGR) of 19.3%. The growth in the historic period can be attributed to emerging market growth, urbanization, increased demand for man-made fibers, and government initiatives for the textile industry.
The alpha mannosidosis market size is expected to see rapid growth in the next few years. It will grow to $34.52 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to global population growth and urbanization, increasing e-commerce, increasing demand for sportswear, increasing penetration of organized retail in developing economies, and increasing penetration of social media. Major trends in the forecast period include increasing the use of enzyme therapy, adopting the use of hematopoietic stem cell transplantation, and adopting the use of cisterna magna infusion.
Get Your Free Sample of The Global Alpha Mannosidosis Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=4093&type=smp
Which industry factors have accelerated the alpha mannosidosis market’s expansion?
The rising demand for precision medicine is expected to propel the growth of the alpha mannosidosis market. Precision medicine is a tailored approach to healthcare that considers individual differences in patients’ genes, environments, and lifestyles to optimize treatment and prevention strategies. The rise in precision medicine is driven by advancements in genomic technologies and data analytics, which enable more accurate identification of genetic variations and their impact on health. Additionally, the increasing demand for personalized treatment options, alongside growing awareness of the limitations of one-size-fits-all approaches, has fueled interest in tailored healthcare solutions. Precision medicine enhances the development of targeted therapies tailored to the specific genetic mutations and patient profiles associated with this rare disorder. For instance, in February 2024, according to the data from the Personalized Medicine Coalition (PMC), a U.S.-based nonprofit umbrella organization reported in 2023 that the FDA approved 16 new personalized treatments for rare diseases, marking a substantial increase from just six approvals in 2022. Therefore, the rising demand for precision medicine is driving the growth of the alpha mannosidosis market.
What are the primary segments of the alpha mannosidosis market?
The alpha mannosidosis market covered in this report is segmented –
1) By Therapy Type: Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT), Other Therapies
2) By Indication: Type I, Type II, Type III
3) By End-User: Hospitals, Speciality Clinics
Subsegments:
1) By Bone Marrow Transplant (BMT): Autologous BMT, Allogeneic BMT
2) By Enzyme Replacement Therapy (ERT): Recombinant Enzymes, Long-acting Enzyme Formulations
3) By Other Therapies: Symptomatic Treatments, Gene Therapy, Supportive Care
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/alphas-mannosidosis-global-market-report
Which firms are leading the alpha mannosidosis market?
Major companies operating in the alpha mannosidosis market include Chiesi Farmaceutici S.p.A., Cipla, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc, Mitsubishi Tanabe Pharma, Merck, Bristol-Myers Squibb, Novartis AG, Amgen, Centogene, Zymenex A/S, Albumedix Ltd, Kite Pharma, Catalent, Freeline Therapeutics, Avectas, DiNAQOR AG, Vivet Therapeutics, Allergan, PsiOxus Therapeutics, Herantis Pharma Plc, Biocad, Celgene Corporation, Johnson & Johnson, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Bayer AG, PTC Therapeutics, Gilead Sciences Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Pfizer S.R.L., AstraZeneca plc, Biogen SA, Sanofi, Adcock Ingram
Which market trends are set to define the future of the alpha mannosidosis market?
Major companies operating in the alpha mannosidosis market are focusing on developing enzyme replacement therapy for rare alpha-mannosidosis. By supplying exogenous alpha-mannosidase, enzyme replacement therapy helps reduce the accumulation of mannose-rich oligosaccharides in various tissues and organs. This accumulation is a characteristic feature of alpha-mannosidosis and contributes to the disease’s pathological effects. For instance, in February 2023, Chiesi Global Rare Diseases a US-based pharmaceutical company launched Lamzede (velmanase alfa), the first enzyme replacement therapy authorized in the United States for the treatment of alpha-mannosidosis, a rare genetic condition marked by an absence of the enzyme alpha-mannosidase in the body, and its manifestations outside of the central nervous system. Lamzede restores normal cellular activity in patients by acting in the same manner as the human body’s alpha-mannosidase enzyme. Once a week, patients receive an injection of 10 mg of Lamzede.
Which geographic trends are shaping the alpha mannosidosis market, and which region has the highest market share?
The countries covered in the alpha mannosidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
What Does The Alpha Mannosidosis Market Report 2025 Offer?
The alpha mannosidosis market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Alpha mannosidosis refers to a rare genetic disorder defined by the body’s cells’ inability to adequately break down specific groups of complex sugars. Numerous bodily organs and systems, including the central nervous system, are impacted by sugar buildup. The disease’s effects might vary greatly from person to person.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=4093
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
